Bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
Severe vaso-occlusive events were eliminated for 94% of evaluable patients and all VOEs were eliminated for 88% of evaluable patients between 6 and 18 months post-infusion LYFGENIA is the most...
Source: marketscreener.com